FibroGen Files 8-K on Security Holder Rights
Ticker: KYNB · Form: 8-K · Filed: Jun 12, 2025 · CIK: 921299
| Field | Detail |
|---|---|
| Company | Fibrogen Inc (KYNB) |
| Form Type | 8-K |
| Filed Date | Jun 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, corporate-action, filing
TL;DR
FIBROGEN filed an 8-K, changes to security holder rights, check for details.
AI Summary
FibroGen, Inc. filed an 8-K on June 12, 2025, reporting a material modification to the rights of security holders and amendments to its articles of incorporation or bylaws. The filing, dated June 10, 2025, indicates changes related to the company's governance or security holder rights, with no specific financial figures or new business developments detailed in the provided text.
Why It Matters
This filing signals potential changes in the rights or structure affecting FibroGen's security holders, which could impact their investment.
Risk Assessment
Risk Level: medium — Filings concerning modifications to security holder rights or corporate bylaws can introduce uncertainty and potential shifts in shareholder value.
Key Players & Entities
- FibroGen, Inc. (company) — Registrant
- June 10, 2025 (date) — Date of earliest event reported
- June 12, 2025 (date) — Date of report
- 350 Bay Street Suite 100 #6009 (address) — Principal Executive Offices
- San Francisco, California (location) — Principal Executive Offices City and State
- 94133 (zip_code) — Principal Executive Offices Zip Code
- 415 978-1200 (phone_number) — Registrant's Telephone Number
FAQ
What specific modifications were made to the rights of FibroGen's security holders?
The provided text of the 8-K filing does not specify the exact nature of the material modifications to the rights of security holders, only that such a modification occurred as of June 10, 2025.
Were there any amendments to FibroGen's Articles of Incorporation or Bylaws?
Yes, the filing indicates that there were amendments to FibroGen's Articles of Incorporation or Bylaws, as reported on June 10, 2025.
What is the primary business of FibroGen, Inc. according to the filing?
FibroGen, Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
When was this 8-K report filed with the SEC?
This 8-K report was filed with the SEC on June 12, 2025.
What is FibroGen's principal executive office address?
FibroGen's principal executive offices are located at 350 Bay Street, Suite 100 #6009, San Francisco, California, 94133.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding FIBROGEN INC (KYNB).